Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease. (PubMed, Curr Opin Rheumatol) - Sep 10, 2026 - "Across these agents, evidence is confined to case reports, small series, and observational cohorts, with few randomized trials reporting IIM-ILD-specific outcomes. Prospective studies are needed to define patient selection, treatment sequencing and combinations, durability, and safety of novel therapies in IIM-ILD."
Journal • Dermatomyositis • Immunology • Interstitial Lung Disease • Melanoma • Myositis • Oncology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Solid Tumor • IFIH1
|
|
Eugene Krustev; Laurence Poirier-Blanchette; Na'ama Avitzur
|